July 9, 2024Open Access

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

Key Points

Key points are not available for this paper at this time.

Abstract

Chemotherapy combined with immunotherapy (CT-IO) is the standard treatment for patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). This study evaluates the effectiveness of second-line (2L) following CT-IO.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Elvire Pons‐Tostivint

Rémy Ezzedine

Thomas Goronflot

Journals

Lung Cancer

Actions

Institutions

Centre National de la Recherche Scientifique

Inserm

Nantes Université

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study